Ultragenyx Pharmaceutical Inc.

NasdaqGS:RARE Stock Report

Market Cap: US$4.0b

Ultragenyx Pharmaceutical Management

Management criteria checks 2/4

Ultragenyx Pharmaceutical's CEO is Emil Kakkis, appointed in Apr 2010, has a tenure of 14.67 years. total yearly compensation is $13.08M, comprised of 6.3% salary and 93.7% bonuses, including company stock and options. directly owns 2.88% of the company’s shares, worth $116.23M. The average tenure of the management team and the board of directors is 9 years and 8.7 years respectively.

Key information

Emil Kakkis

Chief executive officer

US$13.1m

Total compensation

CEO salary percentage6.3%
CEO tenure14.7yrs
CEO ownership2.9%
Management average tenure9yrs
Board average tenure8.7yrs

Recent management updates

Recent updates

Ultragenyx: Ready For More Growth After Q3 Earnings Beat

Nov 12

Ultragenyx: Excellent Company, Lackluster Stock

Nov 06

We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

Sep 04
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective

Aug 22

There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump

Aug 03
There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump

Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being

Jun 12
Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being

Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching

Jun 06

We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

May 24
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet

Mar 09

Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?

Feb 01
Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?

There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise

Dec 28
There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise

Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?

Sep 12
Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?

An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued

May 24
An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued

Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet

Apr 17
Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate

Feb 18
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate

CEO Compensation Analysis

How has Emil Kakkis's remuneration changed compared to Ultragenyx Pharmaceutical's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$559m

Jun 30 2024n/an/a

-US$585m

Mar 31 2024n/an/a

-US$613m

Dec 31 2023US$13mUS$824k

-US$607m

Sep 30 2023n/an/a

-US$635m

Jun 30 2023n/an/a

-US$721m

Mar 31 2023n/an/a

-US$719m

Dec 31 2022US$12mUS$796k

-US$707m

Sep 30 2022n/an/a

-US$678m

Jun 30 2022n/an/a

-US$506m

Mar 31 2022n/an/a

-US$470m

Dec 31 2021US$10mUS$769k

-US$454m

Sep 30 2021n/an/a

-US$356m

Jun 30 2021n/an/a

-US$351m

Mar 31 2021n/an/a

-US$204m

Dec 31 2020US$5mUS$759k

-US$187m

Sep 30 2020n/an/a

-US$256m

Jun 30 2020n/an/a

-US$301m

Mar 31 2020n/an/a

-US$425m

Dec 31 2019US$7mUS$714k

-US$403m

Sep 30 2019n/an/a

-US$397m

Jun 30 2019n/an/a

-US$371m

Mar 31 2019n/an/a

-US$325m

Dec 31 2018US$5mUS$680k

-US$198m

Sep 30 2018n/an/a

-US$192m

Jun 30 2018n/an/a

-US$183m

Mar 31 2018n/an/a

-US$204m

Dec 31 2017US$7mUS$638k

-US$302m

Compensation vs Market: Emil's total compensation ($USD13.08M) is above average for companies of similar size in the US market ($USD6.65M).

Compensation vs Earnings: Emil's compensation has increased whilst the company is unprofitable.

CEO

Emil Kakkis (64 yo)

14.7yrs

Tenure

US$13,077,993

Compensation

Dr. Emil D. Kakkis, M.D., Ph D., is Executive Director of Amlogenyx Inc. Dr. Kakkis has been a Director of Actio Biosciences Inc. since July 2024. He is Venture Advisor of Forge Life Science Partners.He i...

Leadership Team

NamePositionTenureCompensationOwnership
Emil Kakkis
Founder14.7yrsUS$13.08m2.88%
$ 116.2m
Howard Horn
Executive VP of Corporate Strategy & CFO1.2yrsUS$5.94m0.014%
$ 552.3k
Karah Parschauer
Chief Legal Officer & Executive VP of Corporate Affairs8.5yrsUS$4.04m0.017%
$ 669.7k
John Pinion
Chief Quality Operations Officer & Executive VP of Translational Sciences9.4yrsUS$4.05m0.050%
$ 2.0m
Erik Harris
Executive VP & Chief Commercial Officerno dataUS$4.07m0.025%
$ 1.0m
Theodore Huizenga
Senior VP10.9yrsno data0.019%
$ 760.2k
Ernie Meyer
Chief Human Resources Officer & Executive VP4.3yrsno datano data
Thomas Kassberg
Chief Business Officer & Executive VP13.1yrsUS$2.46m0.23%
$ 9.2m
Vimal Srivastava
Senior Vice President of Business Development & Alliance Management6.8yrsno datano data
Dennis Huang
Chief Technical Operations Officer and Executive VP of Gene Therapy Research & Development9.6yrsUS$4.24m0.044%
$ 1.8m
Aaron Olsen
Senior Vice President of Corporate Strategy & Financeno datano datano data
Eric Crombez
Chief Medical Officer & Executive VP1.6yrsno data0.020%
$ 804.2k

9.0yrs

Average Tenure

58yo

Average Age

Experienced Management: RARE's management team is seasoned and experienced (9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Emil Kakkis
Founder14.7yrsUS$13.08m2.88%
$ 116.2m
Daniel Welch
Independent Non-Executive Chairman9.7yrsUS$499.89k0.023%
$ 945.1k
Matthew Fust
Independent Director10.9yrsUS$479.89k0.016%
$ 650.0k
Shehnaaz Suliman
Independent Director5.8yrsUS$466.89k0.016%
$ 650.0k
Deborah Dunsire
Independent Director7.7yrsUS$459.89k0.021%
$ 863.1k
Corazon Sanders
Independent Director3.5yrsUS$469.39k0.0058%
$ 233.7k
Michael Narachi
Independent Director9.8yrsUS$482.39k0.023%
$ 945.1k
Amrit Ray
Independent Director2.7yrsUS$460.39k0.011%
$ 462.6k

8.7yrs

Average Tenure

63yo

Average Age

Experienced Board: RARE's board of directors are considered experienced (8.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 02:01
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ultragenyx Pharmaceutical Inc. is covered by 37 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Michael UlzBaird
Huidong WangBarclays